New cyclooxygenase-2 inhibitors for treatment of experimental autoimmune neuritis
New cyclooxygenase-2 inhibitors for treatment of experimental autoimmune neuritis
复制标题
DOI：
10.1002/mus.10019
复制
发表时间：
2002-02-01
期刊：
影响因子：
3.4
通讯作者：
Akiguchi, I
中科院分区：
文献类型：
--
作者：
Miyamoto, K;Oka, N;Akiguchi, I
我们分析了两种新的环氧合酶-2（考克斯-2）抑制剂塞来昔布（SC-58635）和美洛昔康治疗大鼠实验性自身免疫性神经炎（EAN）的效果，塞来昔布和美洛昔康显著降低了EAN的临床评分和坐骨神经的组织病理学损伤。它们没有引起严重的副作用，而吲哚美辛作为对照引起严重的肠溃疡和肝肾功能障碍。这些研究结果表明，新的考克斯-2抑制剂可能是有用的，作为额外的治疗药物与格林-巴利综合征和慢性炎性脱髓鞘性多发性神经病的患者。(C)2002年John Wiley Sons，Inc.
We analyzed two new cyclooxygenase-2 (COX-2) inhibitors, celecoxib (SC-58635) and meloxicam, for the treatment of experimental autoimmune neuritis (EAN) in rats, Celecoxib and meloxicam significantly reduced clinical EAN score and histopathological damage of the sciatic nerve. They induced no serious side effects, whereas indomethacin used as a control caused severe intestinal ulceration and dysfunction of liver and kidney. These findings suggest that the new COX-2 inhibitors may be useful as additional therapeutic agents for patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy. (C) 2002 John Wiley Sons, Inc.